$NVCR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NovoCure Ltd. Get notifications about new insider transactions in NovoCure Ltd for free.
Page: < prev 1 2 3 4 5 6 7 8 ... 10 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 19 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 84.02 | 443 | 37,220 | 69,504 | 69.9 K to 69.5 K (-0.63 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 83.50 | 2,800 | 233,803 | 69,947 | 72.7 K to 69.9 K (-3.85 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 82.55 | 1,500 | 123,825 | 72,747 | 74.2 K to 72.7 K (-2.02 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 4,743 | 16,316 | 74,247 | 69.5 K to 74.2 K (+6.82 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 5,832 | 20,062 | 0 | |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 20,000 | 68,800 | 5,832 | |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 86.93 | 900 | 78,234 | 87,179 | 88.1 K to 87.2 K (-1.02 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 86.08 | 3,132 | 269,603 | 88,079 | 91.2 K to 88.1 K (-3.43 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 85.35 | 1,800 | 153,634 | 91,211 | 93 K to 91.2 K (-1.94 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 5,832 | 20,062 | 93,011 | 87.2 K to 93 K (+6.69 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 84.01 | 1,439 | 120,886 | 87,179 | 88.6 K to 87.2 K (-1.62 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 83.52 | 12,461 | 1,040,768 | 88,618 | 101.1 K to 88.6 K (-12.33 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.53 | 6,100 | 503,439 | 101,079 | 107.2 K to 101.1 K (-5.69 %) |
Nov 19 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 20,000 | 68,800 | 107,179 | 87.2 K to 107.2 K (+22.94 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 7.03 | 2,407 | 16,921 | 33,979 | |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 20,000 | 68,800 | 25,832 | |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 5,169 | 17,781 | 0 | |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 7.03 | 10,000 | 70,300 | 36,386 | |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 20,000 | 68,800 | 45,832 | |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 10,000 | 34,400 | 5,169 | |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.62 | 504 | 41,642 | 87,179 | 87.7 K to 87.2 K (-0.57 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.80 | 1,403 | 114,771 | 87,683 | 89.1 K to 87.7 K (-1.57 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.96 | 500 | 40,478 | 89,086 | 89.6 K to 89.1 K (-0.56 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 7.03 | 2,407 | 16,921 | 89,586 | 87.2 K to 89.6 K (+2.76 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.54 | 7,200 | 594,252 | 87,179 | 94.4 K to 87.2 K (-7.63 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.67 | 10,800 | 881,993 | 94,379 | 105.2 K to 94.4 K (-10.27 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.78 | 2,000 | 161,556 | 105,179 | 107.2 K to 105.2 K (-1.87 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 20,000 | 68,800 | 107,179 | 87.2 K to 107.2 K (+22.94 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.50 | 1,764 | 145,526 | 87,179 | 88.9 K to 87.2 K (-1.98 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.66 | 2,805 | 229,062 | 88,943 | 91.7 K to 88.9 K (-3.06 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.68 | 600 | 48,409 | 91,748 | 92.3 K to 91.7 K (-0.65 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 5,169 | 17,781 | 92,348 | 87.2 K to 92.3 K (+5.93 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.16 | 2,542 | 206,304 | 87,179 | 89.7 K to 87.2 K (-2.83 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.79 | 7,458 | 602,495 | 89,721 | 97.2 K to 89.7 K (-7.67 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 7.03 | 10,000 | 70,300 | 97,179 | 87.2 K to 97.2 K (+11.47 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.13 | 6,332 | 513,684 | 87,179 | 93.5 K to 87.2 K (-6.77 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.72 | 13,668 | 1,103,240 | 93,511 | 107.2 K to 93.5 K (-12.75 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 20,000 | 68,800 | 107,179 | 87.2 K to 107.2 K (+22.94 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.16 | 2,458 | 199,486 | 87,179 | 89.6 K to 87.2 K (-2.74 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.80 | 7,542 | 609,409 | 89,637 | 97.2 K to 89.6 K (-7.76 %) |
Nov 15 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 10,000 | 34,400 | 97,179 | 87.2 K to 97.2 K (+11.47 %) |
Nov 13 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 5,000 | 17,200 | 4,743 | |
Nov 13 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 79.57 | 5,000 | 397,850 | 69,504 | 74.5 K to 69.5 K (-6.71 %) |
Nov 13 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 5,000 | 17,200 | 74,504 | 69.5 K to 74.5 K (+7.19 %) |
Nov 13 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 82.14 | 2,100 | 172,498 | 809,465 | 811.6 K to 809.5 K (-0.26 %) |
Nov 13 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 81.59 | 11,118 | 907,118 | 811,565 | 822.7 K to 811.6 K (-1.35 %) |
Nov 13 2019 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 80.11 | 29,782 | 2,385,776 | 822,683 | 852.5 K to 822.7 K (-3.49 %) |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 21.15 | 33,793 | 714,722 | 96,651 | |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 22.00 | 36,957 | 813,054 | 0 | |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Option Exercise | M | 14.37 | 10,069 | 144,692 | 0 | |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 79.00 | 33,793 | 2,669,647 | 185,674 | 219.5 K to 185.7 K (-15.40 %) |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 21.15 | 33,793 | 714,722 | 219,467 | 185.7 K to 219.5 K (+18.20 %) |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 79.00 | 36,957 | 2,919,603 | 185,674 | 222.6 K to 185.7 K (-16.60 %) |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 22.00 | 36,957 | 813,054 | 222,631 | 185.7 K to 222.6 K (+19.90 %) |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Sell | S | 79.00 | 10,069 | 795,451 | 185,674 | 195.7 K to 185.7 K (-5.14 %) |
Nov 06 2019 | NVCR | NovoCure Ltd | Ambrogi Michael J. | Chief Operating Off ... | Buy | M | 14.37 | 10,069 | 144,692 | 195,743 | 185.7 K to 195.7 K (+5.42 %) |
Oct 28 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.48 | 4,580 | 34,258 | 32,018 | |
Oct 28 2019 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.48 | 4,580 | 34,258 | 67,721 | 63.1 K to 67.7 K (+7.25 %) |
Oct 15 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 5,000 | 17,200 | 9,743 | |
Oct 15 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 72.28 | 5,000 | 361,400 | 69,504 | 74.5 K to 69.5 K (-6.71 %) |
Oct 15 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 5,000 | 17,200 | 74,504 | 69.5 K to 74.5 K (+7.19 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 7.03 | 1,961 | 13,786 | 58,286 | |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 7.03 | 1,961 | 13,786 | 58,286 | |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 4,031 | 13,867 | 90,632 | |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 4,031 | 13,867 | 90,632 | |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 2,000 | 6,880 | 27,069 | |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Option Exercise | M | 3.44 | 2,000 | 6,880 | 27,069 | |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.56 | 1,661 | 133,804 | 87,479 | 89.1 K to 87.5 K (-1.86 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.56 | 1,661 | 133,804 | 87,479 | 89.1 K to 87.5 K (-1.86 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 7.03 | 1,961 | 13,786 | 89,140 | 87.2 K to 89.1 K (+2.25 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 7.03 | 1,961 | 13,786 | 89,140 | 87.2 K to 89.1 K (+2.25 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.18 | 700 | 56,824 | 87,179 | 87.9 K to 87.2 K (-0.80 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.18 | 700 | 56,824 | 87,179 | 87.9 K to 87.2 K (-0.80 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.50 | 3,331 | 268,155 | 87,879 | 91.2 K to 87.9 K (-3.65 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.50 | 3,331 | 268,155 | 87,879 | 91.2 K to 87.9 K (-3.65 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 4,031 | 13,867 | 91,210 | 87.2 K to 91.2 K (+4.62 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 4,031 | 13,867 | 91,210 | 87.2 K to 91.2 K (+4.62 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 81.19 | 300 | 24,358 | 87,179 | 87.5 K to 87.2 K (-0.34 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.53 | 1,700 | 136,899 | 87,479 | 89.2 K to 87.5 K (-1.91 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Sell | S | 80.53 | 1,700 | 136,899 | 87,479 | 89.2 K to 87.5 K (-1.91 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 2,000 | 6,880 | 89,179 | 87.2 K to 89.2 K (+2.29 %) |
Sep 26 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | CFO | Buy | M | 3.44 | 2,000 | 6,880 | 89,179 | 87.2 K to 89.2 K (+2.29 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 94,663 | |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 119,663 | |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.01 | 22,300 | 1,761,856 | 87,179 | 109.5 K to 87.2 K (-20.37 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.33 | 2,700 | 211,478 | 109,479 | 112.2 K to 109.5 K (-2.41 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.96 | 400 | 32,384 | 87,179 | 87.6 K to 87.2 K (-0.46 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.27 | 13,502 | 1,083,792 | 87,579 | 101.1 K to 87.6 K (-13.36 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.24 | 11,098 | 879,372 | 101,081 | 112.2 K to 101.1 K (-9.89 %) |
Sep 17 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 144,663 | |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 169,663 | |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 81.05 | 201 | 16,291 | 87,179 | 87.4 K to 87.2 K (-0.23 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.51 | 10,107 | 813,694 | 87,380 | 97.5 K to 87.4 K (-10.37 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.42 | 6,499 | 516,151 | 97,487 | 104 K to 97.5 K (-6.25 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.50 | 8,193 | 643,142 | 103,986 | 112.2 K to 104 K (-7.30 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.19 | 4,061 | 321,599 | 87,179 | 91.2 K to 87.2 K (-4.45 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.72 | 11,015 | 867,057 | 91,240 | 102.3 K to 91.2 K (-10.77 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 77.52 | 4,008 | 310,692 | 102,255 | 106.3 K to 102.3 K (-3.77 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 76.37 | 3,974 | 303,478 | 106,263 | 110.2 K to 106.3 K (-3.60 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 75.56 | 1,942 | 146,738 | 110,237 | 112.2 K to 110.2 K (-1.73 %) |
Sep 13 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
Sep 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 3.44 | 5,000 | 17,200 | 14,743 | |
Sep 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 76.63 | 5,000 | 383,150 | 69,504 | 74.5 K to 69.5 K (-6.71 %) |
Sep 12 2019 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 3.44 | 5,000 | 17,200 | 74,504 | 69.5 K to 74.5 K (+7.19 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 194,663 | |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Option Exercise | M | 3.44 | 25,000 | 86,000 | 219,663 | |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 76.45 | 5,709 | 436,447 | 87,179 | 92.9 K to 87.2 K (-6.15 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 75.28 | 19,291 | 1,452,188 | 92,888 | 112.2 K to 92.9 K (-17.20 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 84.41 | 200 | 16,882 | 87,179 | 87.4 K to 87.2 K (-0.23 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.74 | 1,100 | 91,011 | 87,379 | 88.5 K to 87.4 K (-1.24 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 82.05 | 10,800 | 886,129 | 88,479 | 99.3 K to 88.5 K (-10.88 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 80.92 | 4,400 | 356,061 | 99,279 | 103.7 K to 99.3 K (-4.24 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 79.73 | 1,643 | 130,990 | 103,679 | 105.3 K to 103.7 K (-1.56 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Sell | S | 78.70 | 6,857 | 539,673 | 105,322 | 112.2 K to 105.3 K (-6.11 %) |
Sep 11 2019 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Financial Off ... | Buy | M | 3.44 | 25,000 | 86,000 | 112,179 | 87.2 K to 112.2 K (+28.68 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 21.15 | 30,414 | 643,256 | 86,513 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 7.15 | 56,874 | 406,649 | 97,799 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 11,632 | 78,167 | 0 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Option Exercise | M | 6.72 | 59,520 | 399,974 | 0 | |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.86 | 1,200 | 107,828 | 53,900 | 55.1 K to 53.9 K (-2.18 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.86 | 2,900 | 257,703 | 55,100 | 58 K to 55.1 K (-5.00 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.18 | 14,888 | 1,312,794 | 58,000 | 72.9 K to 58 K (-20.43 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.86 | 11,426 | 992,440 | 72,888 | 84.3 K to 72.9 K (-13.55 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 21.15 | 30,414 | 643,256 | 84,314 | 53.9 K to 84.3 K (+56.43 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.87 | 4,031 | 362,262 | 53,900 | 57.9 K to 53.9 K (-6.96 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.97 | 7,869 | 700,129 | 57,931 | 65.8 K to 57.9 K (-11.96 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.22 | 24,083 | 2,124,482 | 65,800 | 89.9 K to 65.8 K (-26.79 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.95 | 20,891 | 1,816,556 | 89,883 | 110.8 K to 89.9 K (-18.86 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 7.15 | 56,874 | 406,649 | 110,774 | 53.9 K to 110.8 K (+105.52 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.97 | 400 | 35,988 | 53,900 | 54.3 K to 53.9 K (-0.74 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.94 | 929 | 82,622 | 54,300 | 55.2 K to 54.3 K (-1.68 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.19 | 6,065 | 534,897 | 55,229 | 61.3 K to 55.2 K (-9.89 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.88 | 4,238 | 368,206 | 61,294 | 65.5 K to 61.3 K (-6.47 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 11,632 | 78,167 | 65,532 | 53.9 K to 65.5 K (+21.58 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 89.90 | 2,300 | 206,759 | 53,900 | 56.2 K to 53.9 K (-4.09 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.82 | 6,616 | 587,620 | 56,200 | 62.8 K to 56.2 K (-10.53 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 88.17 | 28,340 | 2,498,766 | 62,816 | 91.2 K to 62.8 K (-31.09 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 86.85 | 22,264 | 1,933,539 | 91,156 | 113.4 K to 91.2 K (-19.63 %) |
Sep 05 2019 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Buy | M | 6.72 | 59,520 | 399,974 | 113,420 | 53.9 K to 113.4 K (+110.43 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 92.00 | 500 | 46,000 | 134,601 | 135.1 K to 134.6 K (-0.37 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 91.60 | 65,768 | 6,024,612 | 135,101 | 200.9 K to 135.1 K (-32.74 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 90.58 | 57,913 | 5,245,586 | 200,869 | 258.8 K to 200.9 K (-22.38 %) |
Sep 03 2019 | NVCR | NovoCure Ltd | PHILLIPS CHARLES G III | Director | Option Exercise | M | 6.72 | 22,000 | 147,840 | 40,607 |